Our Clients


Inventors • Virtual Start-ups • Pharma • MedTech • VC Firms • Investors • In-Licensing Partners

  • Inventors and Virtual Start-ups – We serve as a complete outsourced R&D division for Virtual Pharma companies.
  • Mid-size BioPharma – We can address Mid-Size pharma firms’ needs, from market evaluation and consulting services to regulatory assistance in filing.
  • Large BioPharma – Global firms look to us for clinical-regulatory strategy and guidance, in tandem with our clinical services.
  • VC Firms and Investors – Venture Capital firms and investors look to us for both consulting and capital services.
  • In-Licensing Partners – We have the clinical, regulatory, and investor expertise to help your company achieve all of its in-licensing goals.

One Goal: Numerous Paths

From preclinical to clinical, from pilot to pivotal, and everything in between, let us help you move through the clinic to commercialization. Ora is dedicated to nurturing the ophthalmic development programs of both individual inventors and virtual start-ups, many of whom look to us for our full complement of services. We are equally dedicated to empowering pharma companies who seek to either launch or expand their presence in the ophthalmic space, providing them with the services they need to augment in-house capabilities.

We also serve as a business liaison between start-up companies, VC firms and investors, and exit partners, assisting them in realizing the highest possible ROI from their novel ophthalmic product candidates.

Our clients choose to work with us because we deliver. We are known for our on-time study completion, knowledgeable staff, and strict protocol adherence.

Prefer to learn from our clients first?

Watch a few of these videos to learn about how our partnership played a strategic role in their success.

In Need of Consulting Services? We can help you at any stage of the process:

  • Clinical development plans
  • Interface with regulatory bodies
  • Conduct and guidance of investor meetings
  • Market sizing and analysis

Let’s start talking

Contact Us